World-First Lung Cancer Vaccine Trials Launched Across Seven Countries

Lung cancer is the world's leading cause of cancer death, with about 1.8m deaths annually.
Survival rates for advanced lung cancer are poor, but a new vaccine, BNT116, aims to change that.
The vaccine, made by BioNTech, targets non-small cell lung cancer (NSCLC) and is in phase 1 trials.
Trials are happening at 34 sites in seven countries, including the UK, US, and Germany.
The vaccine uses mRNA technology to train the immune system to fight cancer cells without harming healthy cells.